tPA Antibody (UK98/6): sc-69740

tPA Antibody (UK98/6) is a mouse monoclonal IgG1 antibody that detects tissue plasminogen activator (tPA) in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). tPA plays a crucial role in the fibrinolytic system, primarily facilitating the breakdown of fibrin in blood clots, which is essential for maintaining normal blood flow and preventing thrombosis. tPA is secreted by endothelial cells and is found in the bloodstream, where anti-tPA antibody (UK98/6) can detect its conversion of plasminogen into plasmin, the active enzyme responsible for degrading fibrin. This process is vital for tissue remodeling and wound healing, as tPA allows for the removal of excess fibrin that can impede healing. tPA is synthesized as a single-chain precursor that undergoes proteolytic cleavage to form a two-chain structure, consisting of an A chain and a B chain, which are linked by a disulfide bond. The regulation of tPA activity is tightly controlled by inhibitors, such as plasminogen activator inhibitor-1 (PAI-1), which ensures that fibrinolysis occurs in a balanced manner, preventing excessive bleeding or clot formation. tPA monoclonal antibody (UK98/6) is an invaluable tool for researchers studying the dynamics of fibrinolysis and its implications in various pathological conditions, including cardiovascular diseases and cancer.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

tPA Antibody (UK98/6) References:

1. Tissue plasminogen activator in psoriasis.  |  Jensen, PJ., et al. 1990. J Invest Dermatol. 95: 13S-14S. PMID: 16788619
2. Conformations of tissue plasminogen activator (tPA) orchestrate neuronal survival by a crosstalk between EGFR and NMDAR.  |  Bertrand, T., et al. 2015. Cell Death Dis. 6: e1924. PMID: 26469972
3. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in diabetic foot syndrome.  |  Kulwas, A., et al. 2017. Adv Med Sci. 62: 87-91. PMID: 28193577
4. Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis.  |  Kou, Y., et al. 2017. Immunol Lett. 190: 51-57. PMID: 28728855
5. Thrombolysis with tissue plasminogen activator (TPA) in feline acute aortic thromboembolism: a retrospective study of 16 cases.  |  Guillaumin, J., et al. 2019. J Feline Med Surg. 21: 340-346. PMID: 29807505
6. The Influence of Tissue Plasminogen Activator I/D Polymorphism on the tPA Response to Exercise.  |  Coughlin, AM., et al. 2018. Int J Exerc Sci. 11: 1136-1144. PMID: 30338017
7. Low-Dose Slow Infusion Tissue Plasminogen Activator (tPA) in Treatment of Thrombotic Coronary Artery Occlusions: Case Series and Literature Review.  |  Akçay, M., et al. 2022. Anatol J Cardiol. 26: 249-257. PMID: 35435835
8. Tissue Plasminogen Activator (t-PA) in a Neonate with Hypernatremic Dehydration.  |  Muppa, V., et al. 2022. Indian J Pediatr. 89: 1054. PMID: 35881215
9. Modulations of the neuronal trafficking of tissue-type plasminogen activator (tPA) influences glutamate release.  |  Varangot, A., et al. 2023. Cell Death Dis. 14: 34. PMID: 36650132
10. Tissue Plasminogen Activator (tPA) Use in Persistent Loculated Ascites.  |  Ali, KM., et al. 2024. Cureus. 16: e72331. PMID: 39583422

The preferred tPA antibody is tPA Antibody (D-1): sc-515562.